SuchaNandMD

PubMed

• Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOG.
  Megan Othus, Ian Thomas, Xu Wang, Cono Ariti, Priyanka Mehta
  Leukemia & Lymphoma. 2023-01-01
• COVID-19 thromboembolism incidence, risk factors, and anticoagulation practices from a Chicago metropolitan US population.
  Stephanie Berg, Seo-Hyun Kim, Amy Wozniak, Oluwatobi Odetola, Saad Arain
  American Journal of Hematology. 2022-06-01
• 8 citations
  Hypercoagulability of COVID-19 and Neurological Complications: A Review.
  Patrick Moore, Fatema Esmail, Shuai Qin, Sucha Nand, Stephanie Berg
  Journal of Stroke and Cerebrovascular Diseases. 2022-01-01

Journal Articles

• Relative Survival Following Response to 7 + 3 Versus Azacytidine Is Similar in Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes: An Analysis of Four SWOG...  
  Sucha Nand, Mikkael A Sekeres, Nature
• Relation between event-free survival and overall survival in acute myeloid leukemia: A report from SWOG, HOVN/SAKK and MRC/NCRI  
  Othus M, van Putten W, Lowenberg B, Petersdorf SH, Nand S, Erba H, Appelbaum F, Hills R, Russell N, Burnett A, Estey E, Haematologica, 1/1/2016
• Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients  
  Achille NJ, Othus M, Phelan K, Zhang S, Cooper K, Godwin J, Appelbaum FR, Radich J, Erba HP, Nand S, Zeleznik-Le N, Leuk Res, 1/1/2016
• Anaplastic large cell lymphoma involving the urinary bladder A case report and review of literature  
  Chen H, Li Y, Nand S, Quek M, Kini A, Barkan G, Diagnostic Cytopathology, 1/1/2014
• Intravascular diffuse large B cell lymphoma A difficult diagnostic challenge  
  Khan M, McCubbin M, Nand S, J Investigative Medicine, 1/1/2014
• Heckathorn’s Disease Revisited  
  Nand S, Barton K, Schultz R, Klein M, Kini A, Blood, 1/1/2014
• Cerebral vein and sinus thrombosis: Risk factors, prognosis and treatment A modern approach  
  Paner A, Jay W, Nand S, Michaelis L, Neuro-ophthalmology, 1/1/2009
• Hydroxyurea, azacytidine and gemtuzumab ozogamicin therapy in previously untreated patients with non-M3 acute myeloid leukemia and high-risk myelodysplastic syndrome i...  
  Nand S, Godwin J, Smith S, Barton K, Michaelis L, Alkan S, Veerappan R, Rychlik K, Germano E, Stiff P, Leukemia and Lymphoma, 1/1/2008
• Single agent lenalidomide induces a response in refractory T-cell post transplant lymphoproliferative disorder  
  Portell C, Nand S, Blood, 1/1/2008
• Hypercoagulable states and the Eye  
  Czerlanis C, Jay W, Nand, S, Seminars in Ophthalmology, 1/1/2008
• Commentary: Blast Crisis in chronic myelogenous leukemia remains a difficult therapeutic challenge  
  Nand S, Barton K, Leukemia and Lymphoma, 1/1/2007
• A unique case of acute promyelocytic leukemia showing monocytic differentiation after all trans-retinoic acid (ATRA) therapy  
  Naeem M, Harrison K, Barton K, Nand S, Alkan S, Eur J Haematol, 1/1/2006
• Thromboembolism in Cancer Patients: Pathogenesis and Treatment  
  Adess M, Eisner R, Nand S, Godwin J, Messmore H, Wehrmacher W, Clinical and Applied Thrombosis/Hemostasis, 1/1/2006
• Survival role of Protein Kinase C (PKC) in chronic lymphocytic leukemia and determination of isoform expression pattern and genes altered by PKC inhibition  
  Alkan S, Huang Q, Ergin M, Denning MF, Nand S, Maududi T, Paner GP, Izban KF, Am J Hematol, 1/1/2005
• Proton Pump Inhibitors and Iron Deficiency: Is the Connection Real?  
  Nand S, Tanvetyanon T, Southern Medical Journal, 1/1/2004
• Pancytopenia in hereditary hemorrhagic telangiectasia  
  Tanvetyanon T, Nand S, Br J Haematol, 1/1/2004
• Overexpression of the NOTCH ligand JAG2 in Malignant Plasma Cells from Multiple Myeloma Patients and Cell Lines  
  Houde C, Li Y, Song L, Barton K, Zhang Q, Godwin J, Nand S, Toor A, Alkan S, Smadja NV, Avet-Loiseau H, Lima C, Miele L, Coignet LJ, Blood, 1/1/2004
• Lymphoproliferative disorders in chronic hepatitis C infection  
  Idilman R, Colantoni A, DeMaria N, Alkan S, Nand S, van Thiel DH, J Viral Hepatitis, 1/1/2004
• Herpes zoster during treatment with arsenic trioxide  
  Tanvetyanon T, Nand S, Ann Hematol, 1/1/2004
• Overcoming recurrent cutaneous reactions from imatinib using once weekly dosing  
  Tanvetyanon T, Nand S, Annals of Pharmacotherapy, 1/1/2003
• Hairy cell leukemia developing in a background of polycythemia vera  
  Kelly NP, Alkan S, Nand, S, Arch Pathol Lab Med, 1/1/2003
• Heparin-Induced Thrombocytopenia and Thrombosis  
  Sun W, Nand S, Resident and Staff Physician, 1/1/1999
• A Phase III Comparison of High Dose Ara-C (HDARC) vs HDARC plus mitoxantrone in the treatment of First-relapsed or Refractory Acute myeloid leukemia A Southwest Oncolo...  
  Karanes C, Kopecky KJ, Grever MR, Hynes HE, Kraut EH, Vial RH, Lichtin A, Nand S, Samlowski WE, Appelbaum F, Leuk Res, 1/1/1999
• MR of Leptomeningeal, spinal and posterior fossa amyloid  
  Horowitz S, Thomas C, Gruener G, Nand S, Shea J, Am J Neuroradiology, 1/1/1998
• A Phase II Trial of Interleukin-2 in Myelodysplastic Syndromes  
  Nand S, Stock W, Stiff P, Sosman J, Martone B, Radvany R, Br J Haematol, 1/1/1998
• Join now to see all

Books/Book Chapters

• Current Neurology and Neuroscience Reports 
  Chapter: Neurological Complications of Leukemias Across the Ages 
  Berg, S, Nand SEditors: Jose Biller.Springer2016
• Anticoagulation for the Neurosurgeon and Hemostasis in Neurosurgery 
  Chapter: Congenital Coagulation Disorders 
  Sterrenberg D, Nand SEditors: Christopher M Loftus.Springer2015
• Anticoagulation for the Neurosurgeon and Hemostasis in Neurosurgery 
  Chapter: Acquired Coagulation Disorders 
  Kruczek K, Cooper K, Mai H, Nand SEditors: Christopher Loftus.Springer2015
• The Handbook of Clinical Neurology-Neurological Aspects of Systemic Disease 
  Chapter: Anemias excluding Cobalamin and Folate Deficincy 
  Dublis, S, Shah S, Nand, S, Anderes EEditors: Jose Biller and Jose Ferro.2010
• The Handbook of Clinical Neurology-Neurological Aspects of Systemic Disease 
  Chapter: Commonly Used Drugs in Hematologic Disorders 
  Anderes E, Nand SEditors: Jose Biller and Jose Ferro.2010
• Neurology of Internal Medicine 
  Chapter: Disorders of Platelets 
  Stillwill JF, Pandya M, Nand S, Michaelis LEditors: Jose Biller, MD.Lippincott Williams and Wilkins, Philadelphia2007
• Neurology of Internal Medicine 
  Chapter: Thrombotic Disorders 
  Broderick W, Nand S, Michaelis LEditors: Jose Biller, MD.Lippincott Williams and Wilkins, Philadelphia2007
• Myelodysplastic Syndromes. Approach to Diagnosis and Treatment 
  Schumacher, H., Nand, S.Williams and Wilkins (Igaku Shoin), Baltimore1995
• Join now to see all

Abstracts/Posters

• Germline Mutations Predispose to Familial Myeloproliferative Neoplasms
  Sucha Nand, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Outcome of patients eligible and ineligible for leukemia studies conducted through SWOG
  Statler A, Othus M, Erba H, Chauncey T, Radich J, Coutre S, Advani A, Nand, S, Ravandi F, Mukherjee S, Sekeres M, ASH, 1/1/2016
• Complete Remissions (CRs) with azacitidine regimens compared to CRs with 7+3 induction chemotherapy and the effect on overall survival
  Othus M, Sekeres MA, Nand, S, Garcia-Manero G, Appelbaum FR, Erba HP, Estey Ethus M, Sekeres MA, Nand, S, Garcia-Manero G, Appelbaum FR, Erba HP, Estey E, ASH, 1/1/2016
• Increased risk of sternal complications in patients with plasma cell dyscrasias undergoing coronary artery bypass graft
  Bufalino S, Patel M, Kothari A, Kuo P, Nand S, Blood, Lymphoma and Myeloma, New York, 1/1/2016
• Prevalence of Multiple Primary Hematologic Malignancies Seen at a Tertiary Care Center
  Cooper K, Lattell J, Gonzalez B, Kleithermes S, Nand S, Blood, 1/1/2015
• Association between early promoter-specific DNA methylation changes and outcome in older acute leukemia patients treated on SWOG S0703 (NCT00658814)
  Nand S, Achille N, Othus M, Phelan K, Zhang S, Cooper K, Godwin J, Appelbaum F, Radich J, Erba H, Zeleznik-Le N, ASCO, 1/1/2015
• Germ-line and somatic mutations in familial myeloproliferative neoplasms (MPNs). A pilot study
  Nand S, Diaz M, Marinier D, Walshauser M, Rosenfeld A, Michaelis L, Stiff P, Gai X, ASH, 1/1/2014
• Sensitizing acute myeloid leukemia cells to interferon-induced differentiation by inhibiting RIP1/RIP3 pathway
  Xin J, You D, Volk A, Zhang J, Li J, Schmidt R, Ni A, Ng G, Wei W, Xia Z, Xiao Y, Gutierrez R, Pan J, Breslin P, Chen H, Kuo P, Nand S, Zhang J, Chen J. Zhang J, ASH, 1/1/2014
• A Phase II trial of azacitidine (NSC-102816) and gemtuzumab ozogamicin (NSC-720568) as induction and post-remission therapy in patients of age 60 or older with previou...
  Nand S, Othus M, Godwin J, Willman C, Norwood T, Erba HP, Howard D, Coutre S, Appelbaum F, ASH, 1/1/2012
• Sensitizing leukemic cells to NFk-B inhibitor treatment by repressing TNF-alpha-mediated, NFk-B independent survival signaling
  Volk A, Xiao Y, Xin J, You D, Schmidt R, Zhang S, Wei W, Breslin P, Nand S, Zhang J, ASH, 1/1/2012
• A Phase II trial of azacitidine (NSC-102816) and gemtuzumab ozogamicin (NSC-720568) as induction and post-remission therapy in patients of age 60 and older with previo...
  Nand S, Gundacker H, Godwin J, Willman C, Norwood T, Erba H, Howard D, Coutre S, Othus M, Appelbaum F, J Clin Oncol, 1/1/2012
• Limitations of performance status (PS) assignment in predicting outcomes of acute myeloid leukemia (AML) and the role of objective parameters in predicting PS assignment
  Phelan KW, Nand S, Michaelis L, Blood, 1/1/2011
• Arsenic trioxide followed by autologous stem cell transplant for patients with relapsed acute promyelocytic leukemia
  Shepard DD, Kohrt HE, Rosenblat TL, Jurcic JG, Park JH, Goldman A, Dalal JS, Maslak PG, Jakubowski AA, Klimek V, Berman E, Nand S, Coutre SE, Tallman MS, Erba HP, J Clin Oncol, 1/1/2011
• Promoter methylation of selected genes and response to azacitidine (AZ) therapy in patients with non BCR-ABL myeloproliferative disorders (MPDs)
  Achille N, Michaelis L, Smith SE, Germano E, Zeleznik-Le N, Nand S, Blood, 1/1/2011
• Azacitidine and low dose gemtuzumab ozogamicin for treatment of poor-risk acute myeloid leukemia and myelodysplastic syndromes including relapsed/refractory disease
  Michaelis L, Shafer D, Stiff P, Nand S, ASH, 1/1/2009
• Treatment of acute myeloid leukemia and high risk myelodysplastic syndrome in the elderly with azacitidine and gemtuzumab ozogamicin
  Nand S, Godwin J, Smith S, Barton K, Germano E, Stiff P, Leukemia Research, 1/1/2007
• Treatment of acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly with azacitidine and gemtuzumab ozogamicin
  Nand S, 9th International Symposium on Myelodysplastic syndromes, Florence, Italy, 1/1/2007
• Azacitidine plus gemtuzumab (GO): a novel combination in the treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) in the elderly
  Nand S, Godwin J, Smith S, Barton K, Germano E, Stiff P, Blood, 1/1/2006
• Allogeneic transplantation for acute myeloid leukemia M2 with 8;21 translocation and CD56 positivity is effective for relapsed disease
  Tanvetyanon T, Nand S, Toor A, Rodriguez T, Parthasarthy M, Stiff P, Blood, 1/1/2004
• A phase I/II study of induction therapy with topotecan, mitoxantrone and etoposide in Relapsed/Refractory AML, Myelodysplasia and Myeloid Blast Crisis
  Nand S., Godwin J., White C., Beltran O., Stiff P., Blood, 1/1/2000
• Protein Kinase C in chronic lymphocytic leukemia. Patterns of Isoform expression and Role in apoptosis
  Pooley R., Ergin M., Denning M.F., Amin H., Nand S., Alkan S., U.S. and Candian Acad of Path, 1/1/1999
• A Phase I/II study of topotecan, mitoxantrone and etoposide n refractory/relapsed AML, myeloid blast crisis and high risk myelodysplastic syndromes
  Nand S., Stiff P., Beltran O., Godwin J., Blood, 1/1/1999
• Home treatment of uncomplicated sickle cell crissis
  Nand S., Zakrzewski S., Vercruysse R., Beleg M., Kareb J., Fisher S.G., Blood, 1/1/1998
• A Phase II Study of Interleukin-2 in Myelodysplastic Syndromes
  Nand S., Stock W., Stiff P., Sosman J., Martone B., Radvany R., Blood, 1/1/1997
• Heparin-induced thrombocytopenia with thrombosis. Risk factors and clinical outcomes in 108 consecutive patients treated at a single institution
  Nand S, Thromb and Haemosta, Florence, Italy, 1/1/1997
• Join now to see all

Lectures

• Cancer-Associated Thromboembolism 
  Loyola University Medical Center - 1/1/2004
• Management of Anemia of Cancer 
  Joliet - 1/1/2002
• Radioimmunotherapy of non-Hodgkin’s Lymphoma 
  Good Samaritan Hospital, Downers Grove, IL - 1/1/2002
• Hypercoagulable States and Cardiovascular System 
  Division of Cardiology, Loyola University Medical Center - 1/10/2003
• Diagnosis of and Approach to Anemias 
  Advocate Lutheran General Hospital, Park Ridge, Illinois - 1/7./2009
• Multiple Myeloma. An Update 
  University of South Dakota, Sioux Falls - 1/13/2005
• Myelodysplastic syndromes. Past, Present and Future 
  Mt Sinai Hospital, Chicago - 1/14/2005
• Perioperative thrombosis and its management 
  Loyola University Medical Center - 1/24/2004
• Chronic Myeloproliferative Disorders 
  Sherman Hospital, Elgin - 1/14/2004
• Anemia in pre-dialysis chronic kidney disease 
  Loyola University Medical Center - 1/8./2004
• New choices in the treatment of Follicular Non-Hodgkin’s Lymphoma 
  Memorial Hospital/Southern Illinois University, Springfield, IL - 1/29/2004
• Radio-immunotherapy. A new therapeutic option for patients with Follicular Non-Hodgkin’s lymphoma 
  Hahneman University Medical center, Philadelphia, PA - 1/1./2003
• Radio-immunotherapy of Follicular Non-Hodgkin’s Lymphoma 
  Thomas Jefferson University Medical Center, Philadelphia, PA - 1/1./2003
• Treatment of Myelodysplastic Syndrome Lessons from the Adult Population 
  Moscow - 1/9./1994
• Management of Cancer-Related Anemia 
  Ingalls Memorial Hospital, Harvey, IL - 1/19/2003
• Myelodysplastic syndromes 
  University of Illinois Medical Center, 2001; St. John’s Mercy Medical Center (University of Missouri - 1/21/2002
• Lymphoproliferative disease and HCV infection 
  Loyola University - 1/16/2000
• Acute Myeloid Leukemia, an Update 
  Cook County Hospital, Chicago - 1/16/2000
• Benign and Malignant Lymphoproliferative disorders associated with Hepatitis C infection 
  Loyola University Medical Center - 1/11/1999
• Heparin-induced Thrombocytopenia with Thrombosis 
  University of Illinois Hospital, Chicago, 1997; St. John’s Mercy Medical Center (University of Misso - 1/11/1999
• Therapeutic Apheresis in Malignancy 
  Kyoto, Japan - 1/4./1996
• Acute Leukemia in Hydroxyurea Treated Polycythemia Vera 
  Bethesda, MD - 1/8./1995
• Join now to see all

Other

• Polycythemia and its neurologic complications 
  Nand S, Kostidis, A, Sarkis Morales-Vidal, MedLink (Online publication)
  1/1/2011